XFOR vs. CTOR, THTX, ACOG, NVCT, NKTX, MOLN, GLSI, BTMD, SKYE, and CRDF
Should you be buying X4 Pharmaceuticals stock or one of its competitors? The main competitors of X4 Pharmaceuticals include Citius Oncology (CTOR), Theratechnologies (THTX), Alpha Cognition (ACOG), Nuvectis Pharma (NVCT), Nkarta (NKTX), Molecular Partners (MOLN), Greenwich LifeSciences (GLSI), biote (BTMD), Skye Bioscience (SKYE), and Cardiff Oncology (CRDF). These companies are all part of the "pharmaceutical products" industry.
X4 Pharmaceuticals vs. Its Competitors
Citius Oncology (NASDAQ:CTOR) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.
Citius Oncology has a beta of 2.92, indicating that its stock price is 192% more volatile than the S&P 500. Comparatively, X4 Pharmaceuticals has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500.
Citius Oncology presently has a consensus target price of $6.00, suggesting a potential upside of 248.84%. X4 Pharmaceuticals has a consensus target price of $34.17, suggesting a potential upside of 1,094.64%. Given X4 Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe X4 Pharmaceuticals is more favorable than Citius Oncology.
Citius Oncology has a net margin of 0.00% compared to X4 Pharmaceuticals' net margin of -311.15%. Citius Oncology's return on equity of -51.93% beat X4 Pharmaceuticals' return on equity.
Citius Oncology has higher earnings, but lower revenue than X4 Pharmaceuticals.
In the previous week, Citius Oncology had 1 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 2 mentions for Citius Oncology and 1 mentions for X4 Pharmaceuticals. X4 Pharmaceuticals' average media sentiment score of 0.95 beat Citius Oncology's score of 0.24 indicating that X4 Pharmaceuticals is being referred to more favorably in the news media.
70.5% of Citius Oncology shares are held by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are held by institutional investors. 6.7% of Citius Oncology shares are held by company insiders. Comparatively, 2.4% of X4 Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Citius Oncology and X4 Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.
Get X4 Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for XFOR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding XFOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
X4 Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:XFOR) was last updated on 10/16/2025 by MarketBeat.com Staff
